COVID-19: Developing platforms to test antivirals against SARS-CoV-2
The Perera lab (in collaboration with the Geiss Laboratory and the CSU OVPR) has mobilized testing of FDA-approved antiviral drugs that can be repurposed and rapidly driven into clinical trials, as well as new compounds that can be evaluated for efficacy against SARS-CoV-2. We are currently working with collaborators and partners from around the world to screen their drug and compound inventories.view project
Metabolite biomarkers of severe disease, resolution and therapeutic efficacy
We utilize Systems Biology based-metabolomics to develop small molecule biosignatures of severe disease. These biosignatures can be utilized for early detection and triaging of patients, to better assist clinical management of those at greater risk. They are also powerful indicators of disease resolution, recurrence and/or therapeutic efficacy.view project
Metabolic basis of mosquito-endosymbiont-virus interactions
These studies will identify biochemical pathways that change in the mosquito following infection with arboviruses, and how the endosymbiont Wolbachia used to control virus transmission in Aedes aegypti may be metabolically competing with the virus. Identifying these pathways that are integral to mosquito biology, provide a novel avenue to interfere with vector transmission of the virus.view project
Exploiting Vulnerabilities in Mosquito Metabolism for Prevention of Human Arboviral Transmissions
Zika, dengue, chikungunya and yellow fever viruses are spread by the same mosquito vector, Aedes aegypti. The Perera lab studies specific metabolic processes in mosquitos required for successful viral replication. These studies will identify metabolic “choke-points” that can be exploited to develop interventions and thus block mosquito-human viral transmission.view project
Metabolic basis of insecticide resistance
We are investigating the metabolic basis of insecticide resistance in Aedes aegypti. We have developed capability to trace the metabolites of insecticides and measure the enzymatic activities responsible for insecticide break down and development of resistance. These studies will assist in driving improvements in insecticide design and informed use of insecticides.view project
Increased serum sialic acid is associated with morbidity and mortality in a murine model of dengue disease.
Espinosa DA, Beatty PR, Puerta-Guardo H, Islam MN, Belisle JT, Perera R, Harris E.
J Gen Virol. 2019 Sep 17. doi: 10.1099/jgv.0.001319. [Epub ahead of print]
Byers NM, Fleshman AC, Perera R, Molins CR.
Viruses. 2019 Mar 6;11(3). pii: E225. doi: 10.3390/v11030225.
Experimental Zika virus infection of Jamaican fruit bats (Artibeus jamaicensis) and possible entry of virus into brain via activated microglial cells.
Malmlov A, Bantle C, Aboellail T, Wagner K, Campbell CL, Eckley M, Chotiwan N, Gullberg RC, Perera R, Tjalkens R, Schountz T.
PLoS Negl Trop Dis. 2019 Feb 4;13(2):e0007071. doi: 10.1371/journal.pntd.0007071. eCollection 2019 Feb.
Stearoly-CoA desaturase 1 differentiates early and advanced dengue virus infections and determines virus particle infectivity.
Gullberg RC, Steel JJ, Pujari V, Rovnak J, Crick DC, Perera R.
PLoS Pathog. 2018 Aug 17;14(8):e1007261. doi: 10.1371/journal.ppat.1007261. eCollection 2018 Aug.
Garcia-Luna SM, Weger-Lucarelli J, Rückert C, Murrieta RA, Young MC, Byas AD, Fauver JR, Perera R, Flores-Suarez AE, Ponce-Garcia G, Rodriguez AD, Ebel GD, Black WC 4th.
PLoS Negl Trop Dis. 2018 Jul 2;12(7):e0006599. doi: 10.1371/journal.pntd.0006599. eCollection 2018 Jul.
news and updates
PhD student Gaby Ramirez details her CSU experience, including conducting COVID-19 and infectious disease research in the Perera lab.
Rushika Perera was received the 2020 Overall Living Our Values Award in the College of Veterinary Medicine and Biomedical Sciences.
Two CSU coronavirus projects were awarded Boettcher Foundation COVID innovation funding.
Lab: Arthropod-borne and Infectious Disease Laboratory (AIDL) room 114